The Isoforms of Proprotein Convertase PC5 Are Sorted to Different Subcellular Compartments

Isabelle De Bie,* Mieczyslaw Marcinkiewicz,‡ Daniela Malide,‡ Claude Lazure,‡ Kazuhisa Nakayama,‡ Moïse Bendayan,‡ and Nabil G. Seidah*

J.A. De Sève *Laboratory of Biochemical Neuroendocrinology, ‡Laboratory of Molecular Neuroendocrinology, and ‡Laboratory of Neuropeptides Structure and Metabolism, Clinical Research Institute of Montréal, Montréal, QC H2W 1R7 Canada (affiliated with Université de Montréal and Protein Engineering Network of Centres of Excellence); ‡Department of Anatomy, Université de Montréal, Succ. Centre-Ville, Montreal, QC H3C 3J7, Canada; and ‡Institute of Biological Sciences and Gene Experiment Center, University of Tsukuba, Tsukuba, Ibaraki 305, Japan

Abstract. The proprotein convertase PC5 is encoded by multiple mRNAs, two of which give rise to the COOH-terminal variant isoforms PC5-A (915 amino acids [aa]) and PC5-B (1877 aa). To investigate the differences in biosynthesis and sorting between these two proteins, we generated stably transfected AtT-20 cell lines expressing each enzyme individually and examined their respective processing pattern and subcellular localization. Biosynthetic analyses coupled to immunofluorescence studies demonstrated that the shorter and soluble PC5-A is sorted to regulated secretory granules. In contrast, the COOH-terminally extended and membrane-bound PC5-B is located in the Golgi. The presence of a sorting signal in the COOH-terminal 38 amino acids unique to PC5-A was demonstrated by the inefficient entry into the regulated secretory pathway of a mutant lacking this segment. EM of pancreatic cells established the presence of immunoreactive PC5 in glucagon-containing granules, demonstrating the sorting of this protein to dense core secretory granules in endocrine cells. Thus, a single PC5 gene generates COOH-terminally modified isoforms with different sorting signals directing these proteins to distinct subcellular localization, thereby allowing them to process their appropriate substrates.

The mammalian subtilisin/kexin-like convertases are proprotein and prohormone proteinases implicated in the processing of numerous precursors. Seven members of this family of enzymes have so far been identified in mammals (for reviews see Seidah et al., 1994, 1996; Van de Ven et al., 1993). These proteins share a conserved catalytic domain, containing the typical Asp/His/Ser triad of subtilisin-like serine proteinases. They also exhibit the presence of a prosegment and a P domain (also called homo B). Apart from these conserved regions, each convertase possesses a distinct COOH-terminal domain exhibiting diverse structural motifs, such as a transmembrane anchor and cytosolic tail, cysteine-rich repeats, or potential amphipathic structures. Furthermore, for three of the mammalian convertases, a differential splicing mechanism leads to the production of COOH-terminally modified isoforms (Seidah et al., 1992; Kiefer et al., 1991; Tsuji et al., 1994; Lusson et al., 1993; Nakagawa et al., 1993a,b; Mbikay et al., 1995). Multiple molecular forms of the convertases are also observed in Aplysia californica (Chun et al., 1994), Hydra vulgaris (Chan et al., 1992), Lymnaea stagnalis (Smit et al., 1992), Caenorhabditis elegans (Thacker et al., 1995), and Drosophila melanogaster (Roebroek et al., 1993).

While functions have been proposed for the pro, catalytic, and P domains of the convertases, the role of the COOH-terminal segment is less understood. It was postulated that the latter could be involved in cellular sorting, or that it could modulate the enzymatic activity of the adjoining catalytic domain. In this respect, ex vivo coexpression studies demonstrated that the COOH-terminal truncation of furin did not affect the cellular enzymatic activity of this convertase on renin or its mutants (Hatsuzawa et al., 1992). It was also reported that the three isoforms of Drosophila furin1 (dfurin1, dfurin1-CRR, and dfurin1-X) did not display significant differences in either their catalytic activity or cleavage specificity (De Bie et al., 1995). Thus, the proposed involvement of the COOH-terminal segment in cellular sorting remains open to investigations.

To test the hypothesis that the COOH-terminal domain influences the cellular transport of some convertases, we compared the cellular traffic of soluble PC5-A and membrane-bound PC5-B (Lusson et al., 1993; also called PC6-A...
and PC6-B, Nakagawa et al., 1993a,b) (see Fig. 1). These COOH-terminal variant isoforms of the mouse convertase PCS exhibit distinct tissue distributions: while expression of PCS-A is widespread, being especially abundant in intestine and adrenals, that of PCS-B is only detected in these two tissues and lung (Lusson et al., 1993; Nakagawa et al., 1993a,b; Seidah et al., 1994). These isoforms were used as models to determine if both would be sorted to the same organelle, or would reside in different compartments of the secretory pathway. To answer this question, stable A1T-20 cell lines expressing either PCS-A or PCS-B were established. This allowed both the comparison of the respective biosynthesis and subcellular localization of each isoform and the demonstration of the critical role of the COOH-terminal domain on the cellular traffic of these proteins.

Materials and Methods

Cell Culture and Transfection

A1T-20 cells were grown in DME supplemented with 10% FCS. Stable cell lines expressing both A and B isoforms of mouse PCS (Lusson et al., 1993) were established using 40-60 ng of RcCMV construct in which these cDNAs were inserted downstream of the human cytomegalovirus promoter. Cells were transfected using lipofectin (GIBCO BRL, Gaithersburg, MD) according to the manufacturer’s instructions. After transfection, cells were selected with 0.5 mg/ml G418 (neomycin)-containing medium for 2-3 wk. Drug-resistant cell lines were isolated and characterized by Western blotting and immunoprecipitation of radiolabeled PCS. For both A and B isoforms, at least six positive clones were selected and analyzed. Initial experiments were performed using several clones for each cell line. Eventually, single clones were used for all experiments (clones A5 for PCS-A and B1 for PCS-B). Cell lines were maintained in 0.2 mg/ml G418-containing medium, passaged weekly, and were stable for several months.

A PCS-A4 construct obtained by PCR (sense primer from bp 2,326-2,348 containing a unique DraI site, and antisense primer introducing a stop codon and XbaI site at base 2,700 [Lusson et al., 1993], in which the COOH-terminal 38 amino acids unique to PCS-A were removed, was similarly transferred to A1T-20 cells to compare its sorting with that of the wild-type PCS-A.

Antibodies

The NH2- and COOH-terminal mouse PCS polyclonal antibodies were obtained by immunization of rabbits using an octopus branched synthetic peptide approach already used for the PCI NH2-terminal antibody (Basak et al., 1995; Benjannet et al., 1993). The peptides chosen consisted of the sequences Pro-Pro-Gly-His-Tyr-His-Ala-Asp-Lys-Lys-Arg-Cys-Arg-Lys, representing residues 677-690 of mouse PCS.

Biochemical Labeling, Immunoprecipitations, and SDS-PAGE Analyses

Biochemical analyses were performed as previously described (Benjannet et al., 1993). Briefly, cells that had reached 80% confluence were washed with PBS, and then switched for 1 h to a methionine- or sulfate-free medium (RPML 1640) (GIBCO BRL) supplemented with 0.5% FCS. Subsequently, cells were either labeled with [35S]methionine (100 μCi/ml) or [35S]Na2SO4 (sodium sulfate) (200 μCi/ml) (Mandel Scientific Co., Ontartio, Canada). To ensure temperature-blocking experiments, cells were preincubated in absence of methionine at 37°C, and then labeled with [35S]methylthionine for 2 h at either 37°C or 20°C. In experiments performed with brefeldin A (Cedarlane Laboratories, Ltd., Ontario, Canada), the drug was used throughout the preincubation and labeling period at a final concentration of 5 μg/ml, as described before (Benjannet et al., 1993). Stimulation of secretion was performed by adding 8Br-cAMP (Sigma Chemical Co., St. Louis, MO) at a final concentration of 5 mM to the incubation medium. At the end of the incubation period, the media were removed and cells were disrupted in lysis buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, and 20 μg/ml PMSF) by incubation on ice for 20 min. The media and cell lysates were precleared in two steps using normal rabbit serum and protein A-agarose, and then immunoprecipitated. All immunoprecipitations were performed as described before (Benjannet et al., 1993). Endoglycosidase H (Oxford Glycosystems, Ltd., Rosedale, NY) digestions were performed according to the manufacturer’s instructions. The immunoprecipitation products were resolved by electrophoresis on 8% polyacrylamide gels (SDS-PAGE) followed by treatment with Entensify (Duo-pont-New England Nuclear, Wilmington, DE) and autoradiography. For preparative purposes, immunoprecipitated proteins were resuspended in 1% SDS-PAGE gels, which were sliced (1 mm). The eluted radiolabeled proteins were subjected to microsequence analysis on a sequenator (model 470A; Applied Biosystems, Foster City, CA) as described (Benjannet et al., 1993).

Electron Microscopy

Pancreatic tissue from five normal Sprague-Dawley rats was fixed by immersion in 1% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4, for 2 h at room temperature, dehydrated in graded methanol, and embedded in either Lowecryl K4M at ~20°C, as previously described (Bendayan, 1984), or in Unicryl (British Biocell Int., Cardiff, UK) at ~20°C (Scala et al., 1992; Malide et al., 1995). Thin-sections were cut, mounted on nickel grids with or without Parlodion-coating, and processed for postembedding colloidal gold immunocytochemistry. For immunolabeling, tissue sections were first transferred for 30 min on a drop of 0.15 M PBS, pH 7.2, containing 0.1% ovolbumin, and then incubated overnight at 4°C with the following anti-
bodies at a dilution of 1:100; rabbit anti-PC2, rabbit anti-PC5, and rabbit anti-glucagon (Incstar Co.). Sections were then rinsed with PBS and incubated for 30 min at room temperature with the protein A-gold complex prepared with 10 nm gold particles (OD_{520} = 0.5), as previously described (Bendayan, 1989; Park and Bendayan, 1992). The grids were then washed with PBS and distilled water, dried, and stained with uranyl acetate before examination. For double immunogold labeling, both sides of the tissue sections were used, according to Bendayan (1982). Combinations of anti-PC2/anti-PC5, anti-PC2/anti-glucagon, and anti-PC5/anti-glucagon antibodies were performed on different faces of the grids in conjunction with protein A-gold complexes formed with 5, 10, or 15 nm gold particles. Several control experiments were carried out to assess the specificity of the labeling obtained. For these controls, incubation was performed with normal serum or specific antibodies preadsorbed overnight with an excess of their corresponding antigens.

**Results**

**Expression of PC5-A and PC5-B in Stably Transfected AtT-20 Cells**

To test the hypothesis that the PC5 isoforms (Fig. 1) could be sorted to different compartments of the secretory pathway, stable transfectants of PC5-A or PC5-B were established in the mouse corticotroph AtT-20 cell line. This cell line was chosen since it has been extensively studied in multiple investigations on the sorting of proteins within the constitutive and regulated pathways (Burgess and Kelly, 1987; Matsuuchi and Kelly, 1991).

The PC5 forms in transfected AtT-20 cells were initially examined by labeling for 2 h with [35S]methionine followed by immunoprecipitation. As shown in Fig. 2, PC5-A-expressing cells produce a major immunoreactive 117-kD protein detected in cell extracts and medium. Immunoprecipitates of the PC5-B-expressing cells revealed the presence in the cell lysate of two PC5-B-specific proteins migrating with an apparent Mₐ of 210 and 170 kD, the latter form also being detected in the medium (Fig. 2). A similar result was obtained after a 4-h pulse in which the 210-kD form of PC5-B was more evident in the cell extracts and was not detected in the medium (data not shown). These data suggest that the sulfated 210-kD form that reached the TGN (Hart, 1992; Baeuerle and Huttner, 1987) is not secretable, indicating that it represents membrane-bound PC5-B. The presence of a shed 170-kD immunoreactive form of PC5-B is reminiscent of the fate of another type I membrane-bound convertase, furin (Rehemtulla et al., 1992), suggesting that COOH-terminal cleavage of the membrane-anchored PC5-B occurs along the secretory pathway. The two bands detected in the cell extracts of an Mₐ of ~95–105 kD are considered nonspecific, as they are also detected in control AtT-20 cells transfected with the RcCMV expression vector alone.

**Precursor–Product Analysis of PC5-A**

The proprotein convertases are initially synthesized aszymogens and must undergo excision of their prosegment before they can be activated (see Fig. 1). To define the organelle in which prosegment cleavage of pro-PC5-A to PC5-A occurs, pulse-chase analysis of the biosynthetic fate of PC5-A in AtT-20 cells labeled with [35S]methionine was undertaken. As shown in Fig. 3, after a 1-min pulse, two immunoreactive PC5 products migrating with an apparent Mₐ of 126 and 117 kD are detected intracellularly. Progressively upon chase, both bands diminish in intensity with the appearance of a 65-kD form 60 min later. At the same time, the secretion of a major 117-kD protein is observed in the medium, as well as that of a relatively minor 65-kD product that becomes more visible after a 120-min chase. Since an NH₂-terminally directed PC5 antibody is used to perform immunoprecipitations, the 65-kD form represents a COOH-terminally shortened fragment of PC5-A. Quantitative scanning of the autoradiogram revealed that in the medium, the ratio of 65 to 117 kD progressively increases from 0.30 to 0.45 during 2–4-h chase periods, respectively (data not shown).

Protein sequencing was then performed to unequivocally establish the identity of the PC5-A protein forms. As shown in Fig. 4, [3H]Tyr⁵ and [3H]Tyr⁹¹ protein sequences were deduced for the 126-kD and the 117-kD forms, respectively. Based on the reported cDNA sequences, the one unique to each isoform is given at the top. A schematic representation of the PC5 primary structure (Lusson et al., 1993), it can be concluded that the 126-kD form is...
pro-PC5-A, the sequence of which begins after the predicted signal peptidase cleavage site CysArgThr↓ArgValTyrThrAsnHis. The 117-kD protein represents PC5-A, which is produced after cleavage of the 82-amino acid prosegment at the sequence ValValLysArgThrLysAspTyrAspLeuSerHisAlaGlnThrTyPheAsnAspProLys. Sufficient amounts of the 65-kD form could not be accumulated to obtain an unambiguous sequence. However, since this fragment is immunoreactive to the NH2-terminal antibody that was raised against the above 15-amino acid peptide starting at the AspTyrAsp... sequence, it likely represents a COOH-terminally truncated product of the 117-kD PC5-A form.

To define whether intracellular zymogen cleavage of the 126-kD pro-PC5-A is an early event, the protein was blocked in anterior secretory pathway compartments using the fungal metabolite brefeldin A (BFA)\(^1\). This agent causes the disassembly of the Golgi complex and fusion of the cis-, medial-, and trans-Golgi (but not the TGN) with the ER (Lippincott-Schwartz et al., 1989, 1991). In the presence of BFA, the conversion of the 126-kD pro-PC5-A into the 117-kD PC5-A is still observed (Fig. 5 a), but COOH-terminal truncation generating the 65-kD product is no longer detected. Thus, NH2-terminal prosegment processing can occur in early compartments of the secretory pathway, but not COOH-terminal truncation. Furthermore, the absence of sulfation of the 126-kD form (Fig. 2) is taken as evidence that pro-PC5-A does not reach the TGN, where sulfation is known to take place (Hart, 1992; Bauerle and Huttner, 1987). Endoglycosidase H digestions were also performed and demonstrated that the 126-kD pro-PC5-A was digested by endoglycosidase H during chase times of up to 4 h, while the intracellular and

---

1. \textit{Abbreviations used in this paper:} BFA, brefeldin A; POMC, pro-opiomelanocortin; TMD, transmembrane domain.
Figure 4. Microsequencing of PC5-A 126- and 117-kD products. The deduced sequence positions of released tritiated residues are indicated, clearly establishing the identity of the 126-kD product as pro-PCS-A and the 117-kD product as zymogen-cleaved PCS-A.

Figure 5. (a) Biosynthesis of PC5-A in the presence of brefeldin A. PC5-A-transfected AtT-20 cells were labeled with [35S]methionine for 2 h in the presence or absence of brefeldin A and immunoprecipitated with an anti-NH2-terminal PC5 antiserum, followed by resolution on 8% SDS-PAGE gels. Molecular masses are given in kD. (b) Effect of 20°C temperature blockade on PC5-A processing. PC5-A-transfected AtT-20 cells were labeled with [35S]methionine at either 20° or 37°C for 2 h and immunoprecipitated with an anti-NH2-terminal PC5 antiserum. A more contrasted exposure is given to clearly establish that the intracellular production of the 65-kD fragment is absent at 20°C. Molecular masses are given in kD.

De Bie et al. PC5 Isoforms Are Sorted to Distinct Subcellular Compartments

secreted 117- and 65-kD forms were resistant to this treatment after a 1-h chase (data not shown).

Since the COOH-terminal truncation generating the 65-kD product does not occur in the presence of BFA (Fig. 5 a), this cleavage must occur in a late compartment of the secretory pathway. To further substantiate this hypothesis, an experiment at a restrictive temperature of 20°C, which traps secretory proteins at the level of the TGN (Matlin and Simons, 1983), was performed. The formation of the 65-kD product was not observed at 20°C (Fig. 5 b). Therefore, COOH-terminal truncation of PC5-A occurs after egress of the 117-kD form out of the TGN.

Cellular Processing of PC5-B

As already shown in Fig. 2, in AtT-20 cells stably transfected with PC5-B, the sulfated protein forms that reach the TGN have an apparent Mr of 210 and 170 kD. Since only the 170-kD form is secreted in the medium, this suggests that the 210-kD sulfated protein is retained intracellularly via the transmembrane domain (TMD). In a similar time course to PC5-A (Fig. 3), pulse labeling of these cells with [35S]methionine for 1 min followed by chase times of up to 2 h demonstrated that the 170-kD COOH-terminally truncated form is first detected in the cell extracts and medium after a 60-min chase period (Fig. 6 a). Since the 170-kD product is detected in the cell extracts, COOH-terminal truncation of PC5-B therefore occurs intracellularly. To determine whether the production of the 170-kD form is an early or late event along the secretory pathway,
Figure 6. (a) Analysis of PC5-B transformations by pulse-chase experiments. PC5-B-transfected cells were pulse labeled with [35S]methionine for 1 min (pl), and then chased (c) for 30, 60, or 120 min, followed by immunoprecipitation. Molecular masses are given in kD. (b) Biosynthesis of PC5-B in the presence of brefeldin A. PC5-B-transfected AtT-20 cells were labeled with [35S]methionine in the presence or absence of brefeldin A for 2 h and immunoprecipitated. Molecular masses are given in kD.

Figure 7. (a) Comparative basal and cAMP-stimulated release of sulfate-labeled PC5-A and PC5-B-encoded proteins: PC5-A is stored in secretory granules, while PC5-B shed form is released through the constitutive pathway. PC5-A- or B-transfected cells were labeled for 2 h with [35S]sulfate and treated with (+) or without (−) 8Br-cAMP. Media were immunoprecipitated with an anti-NH2-terminal PC5 antiserum and resolved by SDS-PAGE. Molecular masses are given in kD. (b) Comparative basal and cAMP-stimulated release of methionine-labeled PC5-A-encoded proteins: both intact and COOH-terminally truncated products are stored in secretory granules. PC5-A-transfected cells were labeled for 2 h with [35S]methionine and treated with (+) or without (−) 8Br-cAMP. Media were immunoprecipitated with an anti-NH2-terminal PC5 antiserum and resolved by SDS-PAGE. Molecular masses are given in kD.

repeated using [35S]methionine labeling. Results shown in Fig. 7 b demonstrate that the release of the 65-kD PC5-A form is also stimulated in presence of 8Br-cAMP. In contrast, the level of the secreted 170-kD PC5-B remains virtually unchanged upon this treatment (Fig. 7 a). The ratio of stimulated over nonstimulated bands was calculated by scanning and quantification of the autoradiograms, and it was found to be 0.90 for PC5-B and 2.5 for PC5-A (average values, see Table I). This suggests that while the 117- and 65-kD forms of PC5-A can enter secretory granules, the shed form of PC5-B (170 kD) exits from the cell via the constitutive secretory pathway (Burgess and Kelly, 1987).

To provide further evidence that the PC5-A sorting signal to secretory granules resides in its COOH-terminal region, a mutant PC5-A construct was produced, in which the last 38 amino acids unique to PC5-A were deleted (see Fig. 1). This mutant PC5-AΔ exhibits a biosynthetic pattern similar to that of PC5-A in pulse-chase experiments, with the presence of 122- and 113-kD forms in the cell extracts (Fig. 8). A notable exception is the production of the 65-kD fragment that, at the 2-h chase period in the me-
30 min with [35S]methionine and chased for the times indicated. Their respective accumulation in the medium was calculated for each chase time by scanning and quantification of the autoradiograms as described in Materials and Methods (Fig. 9). While PC5-A demonstrates secretion kinetics representative of a protein released through the regulated pathway (Grimes and Kelly, 1992; Arvan and Castle, 1987; Chavez et al., 1996), PC5-B and PC5-ΔΔ exhibit notably distinct basal secretion patterns.

**Immunofluorescence Analysis.** To define more precisely the subcellular localization of PC5 proteins, AtT-20 transfected cells were analyzed by immunofluorescence microscopy (Marcinkiewicz et al., 1996). The data in Fig. 10 a show that PC5-A immunoreactivity exhibits a pattern of punctate staining observed in the cytoplasm and at the tips of cellular extensions, known to contain secretory granules (Matsuuchi et al., 1988), and immunostaining at paranuclear positions, which correspond to the Golgi apparatus. Weak immunoreaction could also be seen in the presumptive perinuclear ER. By double immunofluorescence, PC5-A is demonstrated to colocalize with ACTH in secretory granules and Golgi apparatus (Fig. 10, a and b). The PC5-B labeling pattern (Fig. 10 c) is quite different from that observed for either PC5-A or ACTH (Fig. 10, a and b). Immunofluorescence staining of PC5-B (Fig. 10 c) overlaps with that of TGN38 (Fig. 10 d), a TGN-resident protein (Luzio et al., 1990). A mutant PC5-ΔΔ, lacking the PC5-A-specific COOH-terminal segment (PC5-ΔΔelta; Fig. 10 e) also colocalizes with TGN38 by double immunofluorescence (Fig. 10, e and f), showing that this mutant PC5-A seems to reside primarily in compartments anterior to the secretory granules. The specificity of immunolabeling is confirmed by the absence of PC5 immunoreactivity in AtT-20 cells transfected with the RcCMV expression vector alone (Fig. 10 g), and by the displacement of the labeling reaction with excess antigen (data not shown). We note that the labeling pattern of cathepsin B (CB; Fig. 10 h), a marker of lysosomal compartments, is distinct from that observed for PC5 in all our transfected cell lines, although in this case colabeling could not be achieved since both antibodies are from rabbit species.

**Immunocytochemical Evidence of PC5 Localization in Pancreatic Glucagon-secreting Cells by EM**

To demonstrate that the sorting of PC5-A into secretory granules is not fortuitous or the result of overexpression in AtT-20 cells, the cellular localization of PC5 in pancreas was examined by EM. In single-labeling experiments, glucagon immunogold labeling was present over the electron-dense structure of secretory granules, in cells displaying the characteristics of the A cells (Park and Bendayan, 1992) (Fig. 11 a). Using antibodies against the convertases PC2 and PC5 in conjunction with protein A–gold complexes, the gold particles were shown to be associated with the secretory granules of the A cells (Fig. 11, b and c). Double-labeling experiments revealed the colocalization of both PC2 and PC5 within the same granules of the A cells (Fig. 11 d). Double labeling using antibodies to PC2 or PC5 together with a glucagon-specific antibody demonstrated that the majority of glucagon–rich granules also display PC2 or PC5 immunoreactivity (Fig. 11, e and f).

**Discussion**

In this work, the biosynthesis and transport of PC5-A and PC5-B, two isoforms generated from a single gene (Mbikay et al., 1995), were investigated. Specifically, their respec-
Secretion kinetics of PC5 proteins

![Graph](image)

Figure 9. AtT-20-transfected cells were labeled for 30 min with $[^35]S$methionine and chased for the times indicated. Media were immunoprecipitated and resolved by SDS-PAGE. Autoradiographs of these gels were analyzed as described in Materials and Methods to permit quantification of the accumulation of released proteins in the medium at each time point. The calculated band intensities are given in arbitrary units.

![Graph](image)

Figure 10. PC5-A colocalizes with the secretory granules and Golgi apparatus marker ACTH, while PC5-B colocalizes with the TGN marker TGN38. (a) Immunofluorescence analysis of PC5-A intracellular distribution shows density throughout the cytoplasm and at the tips of cellular extensions containing secretory granules (thin arrows) and in paranuclear position, corresponding to a presumptive Golgi apparatus (thick arrow). The pattern of PC5 pancellular distribution much resembles that of ACTH shown in b. Here, as typically seen in AtT-20 cells, ACTH immunoreactivity is found to be spread out over the cell and at the tips of cellular extensions (thin arrows). (c) Intracellular distribution of PC5-B (thick arrows), as detected by immunofluorescence, is comparable to that of the TGN marker TGN38 (d) (thick arrows). The empty arrow depicts lack of PC5 immunoreaction at the tip of the cellular extensions of PC5-B-transfected cells. PC5-A immunofluorescence (e) (thick arrows) is also found to colocalize with TGN38 (f) (thick arrows). (g) Lack of PC5 immunostaining in control AtT-20 cells transfected with the RcCMV vector is depicted by the empty arrows. (h) Cathepsin B (CB) labeling (curved arrows) is markedly different from PC5 labeling observed in PC5-A-, PC5-B-, or PC5-Δ-transfected cells. Bar, 20 μm.

Diverse biosynthetic pattern, sorting, and subcellular localization in stably transfected AtT-20 cells were compared. This work revealed that each isoform resides in a different intracellular compartment, suggesting their distinct functional destinations and the presence within their individual COOH-terminal domains of specific sorting signals.

**Biosynthetic Fates of PC5-A and PC5-B**

Initially, since data were not available on the biosynthesis of PC5, analysis in cells that endogenously express relatively high levels of its mRNA, namely BSC40 cells (Nakagawa et al., 1993a), was attempted. However, detection of sufficient amounts of $[^35]S$methionine-labeled PC5-A above background was unsuccessful. This approach was thus unsuitable to undertake extensive biosynthetic studies on PC5. Hence, the isolation of stable transfectants overexpressing PC5 was preferred, allowing in addition the comparison of the biosynthetic fate and transport of the isoforms PC5-A and PC5-B.

Pulse-chase analysis performed in transfected cells demonstrated that PC5-A is initially produced as pro-PC5-A, and rapidly processed to PC5-A (within a 1-min pulse) in early compartments of the secretory pathway, in a fashion similar to that of the granule-associated convertase PC1 (Benjannet et al., 1993). Pro-PC5-A predominates intracellularly, even after chase periods of up to 2 h (Fig. 3). It is possible that the intracellular predominance of pro-PC5-A over PC5-A at all chase times may be due to its relatively high expression levels in transfectant clones. As assessed by its persistent sensitivity to endoglycosidase H digestion, pro-PC5-A remains in a compartment where transformation and trimming to complex sugar types does not occur (data not shown). With the added observation that pro-PC5-A is not sulfated (Fig. 2), whereas PC5-A is, this suggests that the zymogen remains in the ER, and only the NH2-terminally processed PC5-A is allowed to exit from this compartment. This is in contrast to PC2, which is processed in the TGN/granules (Benjannet et al., 1993). PC5-A also undergoes COOH-terminal truncation into a 65-kD product, presumably within immature secretory granules. This is again similar to the fate of PC1 (87 kD), which is COOH-terminally cleaved into a 66-kD form, also within granules (Vindrola and Lindberg, 1992; Benjannet et al., 1993). Based on its size and the PC5-A sequence (Lusson et al., 1993), and by homology to the...
PC5 isoforms are sorted to distinct subcellular compartments.
physiologically important for the processing of extracellular substrates. A smaller truncation product of 65 kD, such as the one detected for PC5-A, is never observed for PC5-B, even though the cleavage site is present within the region common to both isoforms. Since it was demonstrated that this PC5-A COOH-terminal truncation segment is produced in immature granules, it can be concluded that PC5-B does not enter this compartment.

Although sequencing of the 170-kD form of PC5-B labeled with [3H]tyrosine was attempted several times, it was not possible to obtain unambiguous sequence data, probably as a result of the difficulty of directly sequencing such a large protein (data not shown). The 170-kD protein could be derived from the 210-kD PC5-B by an NH$_2$- and/or COOH-terminal truncation. Since the loss of 40 kD is much greater than that expected for the 9 kD prosegment, it is likely that the 170-kD form is generated by COOH-terminal truncation of the 210-kD PC5-B. Also, the 170-kD product is not retained intracellularly, as would be expected of a form having lost its transmembrane anchor. However, the secreted 170-kD form is presumed to lack the NH$_2$-terminal prosegment as well, sincezymogen forms of either PC1, PC2, or furin are not released from AtT-20 cells (Benjannet et al., 1993). Also, PC5-B activity obtained from recombinant vaccinia virus–infected cells could be detected in vitro in culture media using the fluorogenic substrate pGlu-Arg-Thr-Lys-Arg-methylcoumarin amide (Jean et al., 1993), concomitant with the observation of a 170-kD protein (Seidah, N.G., unpublished results).

**Differential Intracellular Sorting of PC5-A and PC5-B**

When expressed in AtT-20 cells, the two PC5 isoforms were sorted to distinct compartments of the secretory pathway. While the short and soluble PC5-A isoform entered the secretory granules, the membrane-bound PC5-B remained in the Golgi. Immunofluorescence images (Fig. 10 a) agree with the results obtained by biosynthetic labeling (Fig. 7), both of which demonstrate the presence of PC5-A in secretory granules. PC5-A (Fig. 10 a), like ACTH (Fig. 10 b) and PC1 (Marcinkiewicz et al., 1996), exhibits a dual Golgi/granule localization. Since cAMP stimulates the release of both 117-kD and 65-kD forms of PC5-A (Fig. 7 b), the punctate immunofluorescence found throughout the cytoplasm (Fig. 10 a) is presumed to correspond with granules carrying both products. In contrast, immunofluorescence data demonstrate that PC5-B resides in a compartment where it colocalizes with the TGN marker TGN38 (Luzio et al., 1990) (Fig 10, c and d).

To further demonstrate that the sorting of PC5-A to secretory granules is neither an artifact nor the result of overexpression in AtT-20 cells, we performed EM studies to demonstrate the presence of PC5 in the granules of an endocrine tissue. The data (Fig. 11) clearly demonstrate that PC5 colocalizes with both glucagon and PC2 within the granules of the pancreatic A cells. The presence of PC5 in the Golgi could not be established, as a result of the scarcity of this organelle in these cells. Further undertakings are needed to demonstrate the presence of PC5 in the Golgi of pancreatic A cells at the EM level and to determine which form of PC5 prevails in this cellular compartment.

The pancreatic A cells provide a physiological model for the sorting of PC5 in an endocrine tissue. In agreement, in two glucagon-expressing cell lines, the 65-kD PC5-A product has been detected by Western blotting (Blache et al., 1994). One of these cell lines, namely αTC1-6, is derived from the pancreatic A cells (Hamaguchi and Leiter, 1990). This strongly suggests that PC5-A, and not PC5-B, is the species detected in the A cells of the pancreas.

The principal sorting signal that permits PC5-A to enter secretory granules seems to reside within its unique COOH-terminal 38 amino acids. Indeed, a truncation mutant of PC5-A in which this segment was removed was no longer detected in the secretory granules of AtT-20 cells by immunofluorescence microscopy (Fig. 10 e). Moreover, 8Br-cAMP stimulation of the release of this protein only resulted in a 1.2-fold increase of secretion in the medium, while that of wild-type PC5-A could be augmented by up to three times (Table I). Therefore, PC5-AΔ seems to have lost its capacity to efficiently enter secretory granules.

The secretion kinetics of PC5-AΔ are also quite distinct from those of PC5-A. In Fig. 9, where the basal releases of PC5-A, PC5-AΔ, and soluble PC5-B are compared, PC5-A demonstrates a secretion pattern typical of proteins released through the regulated secretory pathway of trans-
Figure 11. EM immunocytochemical detection of PC5 and PC2 in pancreatic glucagon-secreting cells. Pancreatic A cells were immunolabeled with the following antibodies complexed to protein A-gold: anti-glucagon (a, e, and f), anti-PC2 (b, d, and e), and anti-PC5 (c, d, and f). In a, the gold particles complexed to the glucagon antibody are detected over the secretory granules (g). (b) The secretory granules (g) of the A cell are labeled with the PC2 antibody complexed to protein A-gold. (c) Labeling of the A cell with the PC5 antibody complexed to protein A-gold is seen over the majority of secretory granules (g). (d–f) Sections of glucagon-secreting cells were then processed by double immunogold labeling: (d) PC2 (5-nm particles) and PC5 (10-nm particles) are colocalized in the secretory granules (g). (e) PC2 (5-nm particles) is colocalized with glucagon (15-nm particles) in many of the secretory granules. (f) PC5 (5-nm particles) colocalizes with glucagon (15-nm particles) in many granules of the A cell. Bars: (a and b) 0.2 μm; (c–f) 0.1 μm.
formed cell lines, while PC5-AΔ and soluble PC5-B exhibit linear constitutive releases. Tumor-derived endocrine cell lines have been demonstrated to have a high rate of basal, unstimulated release of granule contents. This is especially true of AtT-20 cells (Matsuuchi and Kelly, 1991; Milgram et al., 1994), which release about half of their granule content of ACTH in an unstimulated fashion (Moore et al., 1983). Therefore, Fig. 9 depicts this unstimulated granule exocytosis of PC5-A, which is initially rapid and thought to occur through immature granules, and then reaches a plateau as the protein accumulates in the mature secretory granules.

The basal release of PC5-AΔ and the soluble form of PC5-B, on the other hand, is believed to occur through constitutive vesicles, as their content increases linearly with time in the extracellular medium. The observed rate of release of PC5-B is the lowest of the three PC5 forms, probably because this protein must first undergo excision of its transmembrane domain before being released into the extracellular medium. The fact that the initial rate of release of PC5-A is higher than that of the mutant PC5-AΔ may be due (a) to the fact that the expression levels of PC5-A in the cell lines analyzed are higher than those of PC5-AΔ, and therefore the PC5-A overflow from granules is more important than the constitutive release of the mutant; or (b) to the release of PC5-AΔ from the cell being delayed by the slower rate of exit of this protein out of the ER, as the mutation introduced in the COOH-terminal domain could affect the proper folding of this protein.

The small increase of PC5-AΔ release in the presence of 8Br-cAMP (Fig. 8 b; Table I) could be explained by the entry of this protein in immature secretory granules, as these organelles can release their content upon stimulation (Tooze et al., 1991). This is further supported by the production of a 65-kD truncation product at 37°C, but not at 20°C, by both PC5-A (Fig. 5 b) and PC5-AΔ (data not shown). In comparison, PC5-B is never processed into this smaller truncation product, even though the cleavage site is present within the region common to both isoforms. The differential sorting of PC5-A and PC5-AΔ could therefore occur in immature granules (Arvan and Castle, 1992; Bauerfeind and Huttner, 1993), from which PC5-AΔ could be released through the constitutive-like pathway (Kulawat and Arvan, 1994). Alternatively, PC5-AΔ could enter the immature granules, but then be recycled from this compartment back to the TGN to be released through constitutive vesicles.

**Sequence-specific Sorting Signals of PC5-A and PC5-B**

PC5-A. In an attempt to uncover a potential granule-sorting signal, the sequence unique to PC5-A was tentatively aligned with those of other proteins known to enter the secretory granules, namely chromogranin B and pro-opiomelanocortin (POMC). A consensus sequence emerged that conformed to the signals already defined for chromogranin B (Chanat et al., 1993) and POMC (Cool et al., 1995). This consensus sequence consists of two cysteines, which in the cases of chromogranin B (Chanat et al., 1993) and POMC (Bennett et al., 1986) have been demonstrated to form a disulfide bond, and conserved hydrophobic residues, especially a central leucine (Fig. 12 a). This motif is also observed in chromogranin A (Benedum et al., 1987) and in the convertase PACE4-A (Kiefer et al., 1991). We may therefore have identified a potential granule-sorting signal for PC5-A, which could also be functional in the
conclude that the COOH-terminal 38-amino acid sequence is involved in the sorting of PC5-A to the regulated pathway. This segment may be necessary for the presumed calcium-induced aggregation of PC5-A, allowing its entry into mature secretory granules (Burgess and Kelly, 1987; Tooze et al., 1993). This does not exclude the possibility that additional sorting signals are present in other PC5 domains. Studies with both POMC (Chevrier et al., 1993) and somatostatin (Sevarino and Stork, 1991) demonstrated that multiple sorting signals to the regulated secretory pathway exist in these molecules.

**PC5-B.** Potential signals permitting the retention of PC5-B in Golgi compartments were likewise investigated, by comparing its COOH-terminal–specific sequence to those of other membrane-bound proprotein processing enzymes.

Several trafficking signals governing TGN localization have been recently defined to reside within the cytoplasmic tail of the convertase furin (Molloy et al., 1994; Chapman and Munro, 1994; Voorhees et al., 1995; Schäfer et al., 1995; Jones et al., 1995; Takahashi et al., 1995; Bosshart et al., 1995). These include (a) a cluster of acidic amino acids in the sequence CPSDSEEDEG, where the phosphorylation of both serines by a casein kinase II-like enzyme plays an important modulatory role in the retrieval of furin to the TGN (Jones et al., 1995; Takahashi et al., 1995); (b) a Tyr-containing motif, where the tetrapeptide consensus sequence Y-XX-(hydrophobic) is a necessary and sufficient cytosolic domain signal to retrieve integral membrane proteins from the cell surface to the TGN (Trowbridge et al., 1993); and (c) adjacent leucine and/or isoleucine residues, termed dileucine signal, which has been described as an internalization motif (Johnson and Kornfeld, 1992).

All three signals are present in the cytosolic tail of PC5-B (Fig. 12 b). Two acidic clusters are seen in mouse PC5-B, within the sequence (Nakagawa et al., 1995b): TMD-28aa-SYLDEDQVIEYRDRDYDEDDEDD-19aa-DETEDDE-5aa-COOH, with two potential (Ser and Thr) casein kinase II phosphorylation sites. Both acidic clusters and the casein kinase II phosphorylation site at the serine residue are conserved in rat PC5-B (GenBank accession number: Psk5 V47014). The cytosolic sequence of PC5-B also exhibits four Tyr-containing motifs: TMD-12aa-YEKL-6aa-YSSY-35aa-YRKF-1aa-YGLL-18aa-COOH, which could be potentially functional. Interestingly, PC5-B (LeuLeu, at two positions), furin (LeuLLeu), and PC7 (LeuLeu, at two positions) all contain a dileucine motif within their cytoplasmic tail. Future internalization studies aimed specifically at the tyrosine-containing and/or dileucine signals in this process. Alignment of the known cytosolic tail localization motives of furin, PC7, kexin (Wilcox et al., 1992), and TGN38 (Humphrey et al., 1993; Bos et al., 1993; Wong and Hong, 1993; Ponnambalam et al., 1994; Wilde et al., 1994), all membrane-bound protein residents of the Golgi or TGN, with the motives seen in PC5-B, is shown in Fig. 12 b.

In conclusion, PC5-A and PC5-B constitute the first example for the convertase family of processing enzymes, in which two active forms originating from a single gene exhibit distinct cellular localization. This may represent a mechanism to regulate bioactive enzymes by directing them to different subcellular destinations to process unique sets of precursor substrates. Since the convertases exhibit overlapping tissue distributions as well as in vitro or ex vivo cleavage specificities, the formation of the appropriate convertase/substrate combinations could ultimately be regulated by their particular intracellular localization.

We are grateful to Drs. G. Banting and W. Garten for their gifts of TGN38 antiserum, and to Dr. J. Mort for his gift of catepsin B antiserum. Synthesis of MAP peptides by Dr. Ajoy Basak is much appreciated, as well as the technical assistance of Edwige Marcinkiewicz, Diane Savaria, Anien Lemieux, Suzanne Benjannet, Andrew Chen, Jim Rochomont, Maya Mamarbachi, Joséé Hamelin, Xue-Ween Yuen, Dr. Robert Day, Diane Gingras, Jean Godbout, and Jean Levéillée. Many thanks to Dr. Andrae Laslop for critical reading of the manuscript, to Dr. J. Scott Munzer for countless encouragements, and to Christian Charbonneau for expert handling of photographic material. The secretarial assistance of Mrs. Sylvie Emond and Sandra Gauthier is greatly appreciated.

This work was supported by Medical Research Council of Canada program grants (PG11471, PG11474, MT-12686, and MT-7284), a Protein Engineering Network of Centres of Excellence (PENCE) grant, and J.A. De Sève Succession. J. De Bie received support in part from funds of the PENCE Program and from a scholarship from Fonds pour la Formation de Chercheurs et de la Recherche (Québec, Canada).

Received for publication 7 March 1996 and in revised form 10 September 1996.

**References**

Arvan, P., and J.D. Castle. 1987. Phasic release of newly synthesized secretory proteins in the unstimulated rat exocrine pancreas. *J. Cell Biol.* 104:243-252.

Arvan, P., and J.D. Castle. 1992. Protein sorting and secretion granule formation in regulated secretory cells. *Trends Cell Biol.* 2:327-331.

Baeuerle, P.A., and W.B. Hutter. 1987. Tyrosine sulfation is a trans-Golgi-specific protein modification. *J. Cell Biol.* 105:2655-2664.

Basak, A., A. Boudreauult, A. Chen, M. Chrétien, N.G. Seidah, and C. Lazure. 1995. Application of the multiple antigenic peptides (MAP) strategy to the production of prohormone convertases antibodies: synthesis, characterization and use of B-branched immunogenic peptides. *J. Pept. Sci.* 1:385-395.

Baeuerle, F., and W.B. Hutter. 1993. Biogenesis of constitutive secretory vesicles, secretory granules and synaptic vesicles. *Curr. Opin. Cell Biol.* 5:628-635.

Bendayan, M. 1982. Double immunochemical labeling applying the protein A-gold technique. *J. Histochem. Cytochem.* 30:81-85.

Bendayan, M. 1984. Protein A-gold electron microscopic immunocytochemistry: methods, applications and limitations. *J. Immunol. Methods.* 7:243-270.

Bendayan, M. 1989. Protein A-gold and protein G-gold postembedding immuno-electron microscopy. In *Colloidal Gold: Principles, Methods and Applications*. Vol. 1. M.A. Hayat, editor. Academic Press, San Diego, CA. 33-94.

Benveniste, U.M., A. Lannourcier, D.S. Konecki, P. Rosa, A. Hille, P.A. Baeuerle, R. Frank, F. Lottspeich, J. Mallet, and W.B. Hutter. 1987. The primary structure of human secretorgranin 1 (chromogranin B): comparison with chromogranin A reveals homologous terminal domains and a large intervening variable region. *EMBO (Eur. Mol. Biol. Organ.) J.* 6:1203-1211.

Benjannet, S., N. Rondeau, L. Paquet, A. Boudreauult, C. Lazure, M. Chrétien, and N.G. Seidah. 1993. Comparative biosynthesis, covalent post-translational modifications and efficiency of pro-segment cleavage of the prohormone convertases PC1 and PC2: glycosylation, sulphation and identification of the intracellular site of pro-segment cleavage of PC1 and PC2. *Biochem. J.* 294:735-743.

Bennett, H.P.J., N.G. Seidah, S. Benjannet, S. Solomon, and M. Chrétien. 1986. Protein investigation of the distal bridge arrangements of human proanocortin N-terminal segment (hNt 1-76). *J. Pept. Protein Res.* 27:368-371.

Blache, P., D. Le-Nguyen, C. Boegner-Lemoine, A. Cohen-Solal, D. Bataille, and A. Kervan. 1994. Immunological detection of prohormone convertases in two different proglucagon processing cell lines. *FEBS Lett.* 344:65-68.

De Bie et al. **PC5 Isoforms Are Sorted to Distinct Subcellular Compartments**
Jones, B.G., L. Thomas, S.S. Molloy, C.D. Thnlin, M.D. Fry, K.A. Walsh, and Chevrier, D., H. Fournier, C. Nanlt, M. Zollinger, P. Crine, and G. Boilean. Chavez, R.A., S.G. Miller, and H.-P. Moore. 1996. A biosynthetic regulated secretory pathway in constitutive secretory cells. J. Cell Biol. 133:1177-1191.

Chevrier, D., H. Fournier, C. Nault, M. Zollinger, P. Crine, and G. Boileau. 1993. Targeting of pro-opiomelanocortin to the regulated secretory pathway may involve cooperation between different protein domains. Mol. Cell. Endocrinol. 123:831-844.

Chan, J.Y., J. Korner, T. Kreiner, R.H. Scheller, and R. Axel. 1994. The function and differential sorting of a family of Aplysia proprotein processing endopeptidases. J. Biol. Chem. 269:12129-12136.

Cool, D.R., M. Fenger, C.R. Snell, and Y.P. Loh. 1994. Identification of the cDNA structure of the mouse and rat subtilisin/kexin-like PC5: a candidate for the trans-Golgi network. J. Biol. Chem. 269:10963-10969.

Hamagnchi, K., and E.H. Leiter. 1990. Comparison of cytokine effects on endosomal/lysosomal system. EMBO (Eur. Mol. Biol. Organ.) J. 9:2219-2226.

Humphrey, J.S., L.J. Peters, L.C. Yuan, and J.S. Bouifacino. 1993. Localization of TGN38 is maintained in the trans-Golgi network by a tyrusine-containing motif in the cytoplasmic domain. J. Cell Biol. 120:1125-1134.

Kusumi, K., and T. Ishizaki. 1994. Structure and function of a novel mammalian proprotein convertase: localization to the trans-Golgi network. FEBS Lett. 353:185-189.

Kuliawat, R., and P. Aryan. 1994. Protein targeting via the "constitutive" secretory pathway: involvement of the furin-related proprotein convertase PC2. J. Biol. Chem. 269:17584-17592.

Lee, E.R., L. Lamphigh, N.L. Shepard, and J.S. Mort. 1995. The septoclast, a vacuolar membrane glycoprotein to the cell surface but does not prevent terminal glycosylation. Cell. 23:235-243.

Matlin, K.S., and K. Simons. 1983. Reduced temperature prevents transfer of a membrane glycoprotein to the cell surface but does not prevent terminal glycosylation. Cell. 34:233-243.

Matsushita, L., and R.B. Kelly. 1991. Constitutive and regulated secretion from the endocytic cell line A20. J. Cell Biol. 112:843-852.

Matsushita, L., K.M. Buckley, A.W. Lowe, and R.B. Kelly. 1988. Targeting of secretory vesicles to cytoplasmic domains in A20 and PC12 cells. J. Cell Biol. 109:239-251.

MBikay, M., N.G. Seidah, M. Chrétien, and E.M. Simpson. 1995. Chromosomal assignment of the genes for proprotein convertases PC4, PC5, and PC6 in mouse and human. Genomics. 26:123-129.

Milgram, S., B.A. Eipper, and R.E. Mains. 1994. Differential trafficking of soluble and integral membrane secretory granule-associated proteins. J. Cell Biol. 124:33-41.

Milloy, S.S., L. Thomas, J.K. VanSlyke, P.E. Stenberg, and G. Thomas. 1994. Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. EMBO (Eur. Mol. Biol. Organ.) J. 13:18-33.

Moore, H.-P., B. Oumbier, and R.B. Kelly. 1983. Chloroquine diverts ACTH from A20 to a regulated pathway in A20 cells. Nature (Lond.). 302:434-436.

Nakagawa, T., M. Hosaka, S. Torii, T. Watanabe, K. Murakami, and K. Nakayama. 1994a. Identification of a new member of the mammalian Kex2-like propeptide-processing endoprotease family: its striking structural similarity to PACE4. J. Biochem. 113:132-135.

Nakagawa, T., K. Murakami, and K. Nakayama. 1993b. Identification of an isoform with an extremely large Cy3-rich region of PC6, a Kex2-like processing endopeptidase. FEBS Lett. 278:163-168.

Park, I.S., and M. Bendayan. 1992. Coexistence of glucagon and pancreatic polypeptide in human and rat pancreatic endocrine cells. Endocr. Pathol. 3:134-143.

Ponnambalam, S., C. Rabouille, J.P. Luzio, T. Nilsson, and G. Warren. 1994. The TGN38 glycoprotein contains two non-overlapping signals that mediate localization to the trans-Golgi network. J. Cell Biol. 125:253-268.

Rehemtulla, A., J.D. Orner, and R.J. Kaufman. 1992. Regulation of PACE proprotein-processing activity: requirement for post-endoplasmic reticulum compartment and proteolytic activation. Proc. Natl. Acad. Sci. USA. 89:8235-8239.

Roebroeck, A.J.M., J.W.M. Creemers, I.G.L. Puij, T. Bogaert, and W.J.M. Van de Ven. 1993. Generation of structural and functional diversity in furin-like proteins in Drosophila melanogaster by alternative splicing of the Dfure1 gene. EMBO (Eur. Mol. Biol. Organ.) J. 12:1853-1870.

Scala, C., G. Cenacchi, C. Ferrari, G. Pasquinettili, P. Preds, and G.C. Mainara. 1992. Demonstration of a new acryllic structural compartment and integral membrane secretory granule-associated proteins. J. Histochem. Cytochem. 40:1799-1804.

Schäfer, W., A. Stroh, S. Bergblöter, J. Seiler, M. Vey, M.-L. Kruse, H.F. Kern, H. Frenk, and W. Garten. 1995. Two independent targeting signals in the cytoplasmic domain determine the trans-Golgi network localization and endosomal trafficking of the proprotein convertase furin. EMBO (Eur. Mol. Biol. Organ.) J. 14:2424-2435.

Seidah, N.G., R. Day, J. Hamamoto, A. Gaspar, W.M. Collard, and M. Chrétien. 1992. Testicular expression of PC4 in the rat: molecular diversity of a novel germ cell-specific Kex2/Subtilisin-like proprotein convertase. Mol. Endocrinol. 6:1519-1527.

Seidah, N.G., M. Chrétien, and R. Day. 1994. The family of subtilisin/keixin-like proprotein and pro-hormone convertases: divergent or shared functions. Biochimie (Paris). 76:197-209.

Seidah, N.G., J. Hamamoto, M. Marabuchi, W. Dong, H. Tadros, M. Mbikay, M. Takahashi, S., T. Nakagawa, T. Banno, T. Watanabe, K. Murakami, and K. Nakayama. 1995. Localization of furin to the trans-Golgi network and recycling from the cell surface involves Ser and Tyr residues within the cytoplasmic domain. J. Cell Biol. 120:28397-28401.
Thacker, C., K. Peters, M. Srayko, and A. Rose. 1995. The bli-4 locus of Caenorhabditis elegans encodes structurally distinct Kex2/subtilisin-like endoproteases essential for early development and adult morphology. Genes & Dev. 9:956–971.

Tooze, S.A., T. Flatmark, J. Tooze, and W.B. Huttner. 1991. Characterization of the immature secretory granule, an intermediate in granule biogenesis. J. Cell Biol. 115:1491–1503.

Trowbridge, I.S., J.F. Collawn, and C.R. Hopkins. 1993. Signal-dependent membrane protein trafficking in the endocytic pathway. Annu. Rev. Cell Biol. 9:129–161.

Tsuji, A., K. Higashine, C. Hine, K. Mori, Y. Tamai, H. Nagamune, and Y. Matsuda. 1994. Identification of novel cDNAs encoding human kexin-like protease, PACE4 isoforms. Biochem. Biophys. Res. Comm. 200:943–950.

Van de Ven, W.J.M., A.J.M. Roebroek, and H.J.P. Van Duijnhoven. 1993. Structure and function of eukaryotic proprotein processing enzymes of the subtilisin family of serine proteases. Crit. Rev. Oncog. 4:115–136.

Vey, M., W. Schäfer, S. Berghöfer, H.-D. Klenk, and W. Garten. 1994. Maturation of the trans-Golgi network protease furin: compartmentalization of propeptide removal, substrate cleavage, and COOH-terminal truncation. J. Cell Biol. 127:1829–1842.

Vindrola, O., and I. Lindberg. 1992. Biosynthesis of the prohormone convertase mPC1 in AT-20 cells. Mol. Endocrinol. 6:1088–1094.

Voorhees, P., E. Deignan, E. van Donselaar, J. Humphrey, M.S. Marks, P.J. Peters, and J.S. Bonifacino. 1995. An acidic sequence within the cytoplasmic domain of furin functions as a determinant of trans-Golgi network localization and internalization from the cell surface. EMBO (Eur. Mol. Biol. Organ.) J. 14:4961–4975.

Wilcox, C.A., K. Redding, R. Wright, and R.S. Fuller. 1992. Mutation of a tyrosine localization signal in the cytosolic tail of yeast Kex2 protease disrupts Golgi retention and results in default transport to the vacuole. Mol. Biol. Cell. 3:1353–1371.

Wilde, A., C. Dempsey, and G. Banting. 1994. The tyrosine-containing internalization motif in the cytoplasmic domain of TGN38/41 lies within a nascent helix. J. Biol. Chem. 269:7131–7136.

Wong, S.H., and W. Hong. 1993. The SXYQRL sequence in the cytoplasmic domain of TGN38 plays a major role in the trans-Golgi network localization. J. Biol. Chem. 268:22853–22862.

Zhou, Y., and I. Lindberg. 1994. Enzymatic properties of carboxyl-terminally truncated prohormone convertase 1 (PC1/SPC3) and evidence for autocataytic conversion. J. Biol. Chem. 269:18408–18413.